H.C. Wainwright analyst Ram Selvaraju downgraded Vical Inc (VICL) to Hold today. The company’s shares closed on Friday at $1.05.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.9% and a 37.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Vical Inc has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on Vical Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.61 million. In comparison, last year the company had a GAAP net loss of $3.73 million.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
